IP Verse

Eisai R&d Management Co., Ltd. competitive analysis

Latest patents of Eisai R&d Management Co., Ltd. opposed by its competitors

Explore Eisai R&d Management Co., Ltd.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4121007
Jul 2, 2025High Concentration Anti-Ass Protofibril Antibody Formulations And Methods Of Use Thereof1
EP3861346
Jan 8, 2025Biomarkers For A Therapy Comprising A Sorafenib Compound1
EP3581183
Nov 29, 2023Tumor-Treating Pharmaceutical Composition1
EP3263106
Oct 25, 2023Method For Suppressing Bitterness Of Quinoline Derivative8
EP3524595
Aug 10, 2022High-Purity Quinoline Derivative And Method For Manufacturing Same9
EP3265122
May 4, 2022Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer4
EP3338779
Jun 30, 2021Tumor Therapeutic Agent1
EP2665732
Mar 30, 2016Fused Aminodihydrothiazine Derivatives Useful As Bace Inhibitors1
EP2036557
Oct 21, 2015Antitumor Agent For Thyroid Cancer2
EP2233474
Aug 5, 2015Condensed Aminodihydrothiazine Derivative1

Latest PTAB cases involving Eisai R&d Management Co., Ltd.

Discover the latest PTAB cases involving Eisai R&d Management Co., Ltd., highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Eisai R&d Management Co., Ltd. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
EISAI R&D MANAGEMENT - 30 - -
ACCORD HEALTHCARE44 - 4 -
GENERICS UK319 - - -
STADA ARZNEIMITTEL15332 - -